These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12763689)

  • 1. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
    Holmgren J; Czerkinsky C; Eriksson K; Mharandi A
    Vaccine; 2003 Jun; 21 Suppl 2():S89-95. PubMed ID: 12763689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in mucosal vaccines and adjuvants.
    Eriksson K; Holmgren J
    Curr Opin Immunol; 2002 Oct; 14(5):666-72. PubMed ID: 12183170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles.
    Greer CE; Petracca R; Buonamassa DT; Di Tommaso A; Gervase B; Reeve RL; Ugozzoli M; Van Nest G; De Magistris MT; Bensi G
    Vaccine; 2000 Dec; 19(9-10):1008-12. PubMed ID: 11137233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects.
    Sánchez J; Holmgren J
    Cell Mol Life Sci; 2008 May; 65(9):1347-60. PubMed ID: 18278577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.
    Hartman AB; Van De Verg LL; Venkatesan MM
    Infect Immun; 1999 Nov; 67(11):5841-7. PubMed ID: 10531238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal delivery of vaccines.
    Del Giudice G; Pizza M; Rappuoli R
    Methods; 1999 Sep; 19(1):148-55. PubMed ID: 10525451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
    Yamamoto M; McGhee JR; Hagiwara Y; Otake S; Kiyono H
    Scand J Immunol; 2001 Mar; 53(3):211-7. PubMed ID: 11251876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal adjuvants.
    Stevceva L; Ferrari MG
    Curr Pharm Des; 2005; 11(6):801-11. PubMed ID: 15777234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the immune response by the cholera-like enterotoxins.
    Plant A; Williams NA
    Curr Top Med Chem; 2004; 4(5):509-19. PubMed ID: 14965302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholera toxin and related enterotoxins as potent immune modulators.
    Hirst TR; Nashar TO; Pitman RS; Williams NA
    Symp Ser Soc Appl Microbiol; 1998; 27():26S-34S. PubMed ID: 9750359
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent developments in mucosal immunomodulatory adjuvants.
    Harandi AM; Sanchez J; Eriksson K; Holmgren J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):156-61. PubMed ID: 12669375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.